NCT03308396View on ClinicalTrials.gov

Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

December 19, 2017

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2023

Conditions
Advanced Kidney CancerKidney CancerClear Cell Renal Cell Carcinoma
Interventions
DRUG

Guadecitabine

Days 1-5 Dose 0: 60 mg/m\^2 Dose -1: 45 mg/m\^2

DRUG

Durvalumab

Day 8 Durvalumab (1500 mg IV)

Trial Locations (5)

17033

Penn State Cancer Institute, Hershey

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

52242

University of Iowa Hosptials and Clinics, Iowa City

60612

Univerisity of Illinois Cancer Center, Chicago

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

Big Ten Cancer Research Consortium

OTHER

lead

Ajjai Alva, MD

OTHER